- Home
- BNR vs BOLD Comparison
BNR vs BOLD Comparison
Compare BNR & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNR
- BOLD
- Stock Information
- Founded
- BNR 2014
- BOLD 2018
- Country
- BNR China
- BOLD United States
- Employees
- BNR N/A
- BOLD N/A
- Industry
- BNR Medical Specialities
- BOLD
- Sector
- BNR Health Care
- BOLD
- Exchange
- BNR Nasdaq
- BOLD Nasdaq
- Market Cap
- BNR 38.3M
- BOLD 33.4M
- IPO Year
- BNR 2020
- BOLD 2024
- Fundamental
- Price
- BNR $12.25
- BOLD $1.25
- Analyst Decision
- BNR
- BOLD Buy
- Analyst Count
- BNR 0
- BOLD 4
- Target Price
- BNR N/A
- BOLD $4.00
- AVG Volume (30 Days)
- BNR 33.9K
- BOLD 143.3K
- Earning Date
- BNR 12-02-2025
- BOLD 11-05-2025
- Dividend Yield
- BNR N/A
- BOLD N/A
- EPS Growth
- BNR N/A
- BOLD N/A
- EPS
- BNR N/A
- BOLD N/A
- Revenue
- BNR $74,862,782.00
- BOLD N/A
- Revenue This Year
- BNR $136.32
- BOLD N/A
- Revenue Next Year
- BNR N/A
- BOLD N/A
- P/E Ratio
- BNR N/A
- BOLD N/A
- Revenue Growth
- BNR 5.20
- BOLD N/A
- 52 Week Low
- BNR $2.18
- BOLD $1.00
- 52 Week High
- BNR $13.89
- BOLD $3.75
- Technical
- Relative Strength Index (RSI)
- BNR 60.87
- BOLD 40.98
- Support Level
- BNR $11.31
- BOLD $1.37
- Resistance Level
- BNR $12.71
- BOLD $1.52
- Average True Range (ATR)
- BNR 1.04
- BOLD 0.07
- MACD
- BNR 0.09
- BOLD -0.03
- Stochastic Oscillator
- BNR 72.11
- BOLD 6.25
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.